Savara Inc. (NASDAQ: SVRA) will present new data from its Phase 3 IMPALA-2 clinical trial at the American Thoracic Society ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE